Navigation Links
Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented at American Society of Clinical Oncology Annual Meeting -

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that treatment with epratuzumab plus standard chemotherapy is feasible and well tolerated in children with B-precursor acute lymphoblastic leukemia (ALL), producing favorable early responses in the majority of patients. Elizabeth Raetz, MD, pediatric oncologist at New York University, New York, in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, reported results from this multicenter feasibility/phase II study.

Fifteen patients with CD22-positive ALL in marrow relapse were enrolled in the feasibility portion of the study. Nine patients were in first and 3 in second or later marrow relapse. Epratuzumab was given alone at 360 mg/m2 twice weekly for two weeks followed by 4 weekly doses of epratuzumab in combination of standard cytotoxic chemotherapy. Within 24 hours of the 6-week treatment period, surface CD22 antigen was not detected on peripheral blood leukemic blasts in all but one of the 12 assessable patients, indicating effective targeting of leukemic cells by epratuzumab. At the time of reporting, 9/12 patients (75%) achieved a complete remission, of whom 7 showed no residual disease by flow cytometry; 1 patient had a partial response, 1 stable disease, and 1 with disease progression.

"We are encouraged by these results. The phase-2 portion of the study is now opened for enrollment of 112 patients, with a primary endpoint of second complete remission rate," commented Dr. Raetz, the study chair.

"We are pleased that COG shares our enthusiasm for epratuzumab and has chosen to evaluate our antibody in the
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
8. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
9. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
10. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
11. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
Post Your Comments:
(Date:5/29/2015)... May 29, 2015 /CNW/ - Covalon Technologies Ltd. (the ... technologies company, is delighted to announce its financial ... 2015, which includes revenue for three months of ... $264,340. Revenue from advanced wound care product sales for ... increased 24% to $1,742,672 compared to $1,400,065 for ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... May 02, 2007 /PRNewswire/ -- Ceregene, Inc.,today presented interim ... gene therapy product designed to deliver nerve growth,factor (NGF) ... follow-up, the results for the six patients who received,CERE-110 ... the,therapy was well tolerated, and an interim analysis suggested ...
... CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - ... sclerosis (RRMS),patients treated with COPAXONE(R) (glatiramer ... experienced a,90 percent reduction in magnetic ... their baseline. These benefits were,achieved early ...
Cached Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... 2015 What does community do? , ... community comes together to plant gardens, to teach young ... awareness of critical issues. Community invites everyone to help ... , "What Community Does" was commissioned by The Denver ... and released during the foundation’s Annual Celebration in May. ...
(Date:5/29/2015)... Rhode Island (PRWEB) May 29, 2015 ... 7, 2015. The event, now closed to new registration, ... Fort Adams. This exciting competitive running event demonstrates ... organizations to create a public benefit – in this ... scenic coastal views around the famed Ocean Drive and ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... 2015 According to a recent HealthDay article, ... workers has a substance abuse problem - the data, which ... adults with full-time jobs, revealed that 9.5% of those workers ... (1) The National Council on Alcoholism and Drug Dependence (NCAAD) ... an estimated 70% of the 14.8 million illicit drug users ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... Caused Public Health CrisisEditor,s Note: Complete report including ... . WASHINGTON, Jan. 13 The American Lung ... 2008 report today, which includes a report ... federal laws to protect citizens from tobacco caused ...
... groundbreaking case that could,affect one-third of American families, Cook ... a 10 month old child with a severe heart,condition ... also gave the,father custody of his 3 year old ... unusual because most courts have not recognized stepfathers,as having ...
... Tenn., Jan. 13 The National Eczema Association (NEA) ... and Theraplex Clear Lotion .The NEA Seal ... Sensitive-Skin Education (EASE) program, which is intended to improve ... eczema and sensitive skin. "These products met our criteria ...
... meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical has ... season beginning in August. , ... (Vocus) January 13, ... Flu Vaccine for the 2009-2010 flu season. They ...
... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ... Julia M. Fisher, Western Medical Product Manager. , ... Westlake, OH (PRWEB) ... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ...
... New research out of Wake Forest University Baptist Medical ... used to relieve symptoms of cough and congestion, may ... , The study appears in this month,s issue ... American College of Chest Physicians, and reports that the ...
Cached Medicine News:Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 2Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 3Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Low Cost Oxygen Regulator: Pay Less For Quality 2Health News:Popular cold and cough treatment may create respiratory distress in young children 2Health News:Popular cold and cough treatment may create respiratory distress in young children 3
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: